Effects of Resveratrol Co-Administration on Celecoxib Disposition and Pharmacokinetics in Healthy Volunteers.
Nagwa I HelalNoha M El-KhodaryGamal A OmranSoha M El-MasryPublished in: Drug research (2023)
The objective of the current study was to investigate the effects of resveratrol (RSV), a natural herbal remedy used as an adjacent anti-inflammatory supplement on, the pharmacokinetics of celecoxib in healthy male volunteers. Twelve healthy human participants were involved in two-period open-labeled trial. Celecoxib (200 mg) was given as a single oral dose under fasting conditions as a control phase. Afterward, RSV (500 mg) commenced as a single oral dose for ten days as a treatment phase. Blood samples were collected during the control and treatment phases and analyzed using the validated High-performance liquid chromatography (HPLC) method. RSV pre-exposure significantly increased the area under the curve (AUC 0-24 ), peak plasma concentration (C max ), absorption rate constant (ka), and prolongated half-life (t 1/2 ), along with a decrease in elimination rate constant (ke). Meanwhile, the volume of distribution (Vd/F) and apparent total body clearance (CL/F) were significantly decreased for celecoxib. There was no significant change in the time it takes for celecoxib to reach the maximum concentration (t max ) was observed. The obtained results suggested the presence of a beneficial pharmacokinetic interaction between RSV and celecoxib. Consequently, combining resveratrol as an herbal remedy and celecoxib as an anti-inflammatory drug may synergistically reduce inflammation and osteoarthritis with minimal side effects.
Keyphrases
- high performance liquid chromatography
- anti inflammatory
- respiratory syncytial virus
- respiratory tract
- mass spectrometry
- simultaneous determination
- oxidative stress
- endothelial cells
- minimally invasive
- type diabetes
- magnetic resonance imaging
- computed tomography
- blood glucose
- randomized controlled trial
- metabolic syndrome
- phase iii
- magnetic resonance
- combination therapy
- knee osteoarthritis
- phase ii
- positron emission tomography
- pet ct
- double blind